

<b>Patient Name</b> SAMPLEREPORT,FABMS	<b>Patient ID</b> SA00046667	<b>Age</b> 45	<b>Gender</b> F	<b>Order #</b> SA00046667
<b>Ordering Phys</b>				<b>DOB</b> 06/10/1966
<b>Client Order #</b> SA00046667	<b>Account Information</b> C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			<b>Report Notes</b>
<b>Collected</b> 05/20/2012				
<b>Printed</b> 09/15/2012 11:55				

Test	Flag	Results	Unit	Reference Value	Perform Site*
<b>Fabry Disease Full Gene Analysis</b>			REPORTED 07/13/2012 10:03		
Specimen		Blood			MCR
Specimen ID		1038189			MCR
Order Date		21 May 2012 14:57			MCR
Reason For Referral		Patient reported to have features of Fabry or variant Fabry disease. Test for the presence of a mutation in the GLA gene.			MCR
Method		Bi-directional sequence analysis was used to test for the presence of a mutation in all coding regions and intron/exon boundaries of the GLA gene. Mutation nomenclature is based on GenBank accession number NM_000169.2.			MCR
Result		A mutation was NOT detected.			MCR
Interpretation		This result decreases the likelihood, but does not rule out the diagnosis of Fabry disease or variant Fabry disease. We predict that there may be disease causing mutations in the GLA gene that are not identified by the method described (e.g., large deletions/duplications, promoter mutations, or deep intronic mutations). This assay does not rule out the presence of disease causing mutations in other genes associated with metabolic disease.  This result should be interpreted in the context of clinical findings, family history, and other laboratory testing (e.g., alpha-galactosidase activity in leukocytes and ceramide trihexoside/sulfatide accumulation in urine sediment).  A genetic consultation may be of benefit.  Unless reported or predicted to cause disease, alterations found deep in the intron or alterations that do not result in an amino acid substitution are not reported. These and common polymorphisms identified for this patient are available upon request.  CAUTIONS: Test results should be interpreted in context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.			MCR

\*\*\*Performing Site Legend on Last Page of Report\*\*\*

<b>Patient Name</b> SAMPLEREPORT,FABMS	<b>Collection Date and Time</b> 05/20/2012	<b>Report Status</b> Final
Page 1 of 2		>> Continued on Next Page >>

\* Report times for Mayo performed tests are CST/CDT

<b>Patient Name</b> SAMPLEREP, FABMS	<b>Patient ID</b> SA00046667	<b>Age</b> 45	<b>Gender</b> F	<b>Order #</b> SA00046667
<b>Ordering Phys</b>				<b>DOB</b> 06/10/1966
<b>Client Order #</b> SA00046667	<b>Account Information</b> C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER, MN 55901			<b>Report Notes</b>
<b>Collected</b> 05/20/2012				
<b>Printed</b> 09/15/2012 11:55				

Test	Flag	Results	Unit	Reference Value	Perform Site*
------	------	---------	------	-----------------	---------------

Rare polymorphisms exist that could lead to false negative or positive results. If results obtained do not match the clinical findings, additional testing should be considered.

Bone marrow transplants from allogenic donors will interfere with testing. Call Mayo Medical Laboratories for instructions for testing patients who have received a bone marrow transplant.

Laboratory developed test.

Reviewed By

Melody Elizabeth Kimball

MCR

Release Date

13 Jul 2012 10:00

MCR

\* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director:
-----	---	---------------

<b>Patient Name</b> SAMPLEREP, FABMS	<b>Collection Date and Time</b> 05/20/2012	<b>Report Status</b> Final
Page 2 of 2		** End of Report **

\* Report times for Mayo performed tests are CST/CDT